Spleen irradiation in chronic lymphocytic leukemia (CLL): palliation in patients unfit for splenectomy.
In 22 patients with CLL given 30 courses of spleen irradiation, 23 responses were observed (77%, 95% confidence limits, 58-90%). Response was defined as reduction in palpable spleen size accompanied by relief of symptoms (pain, abdominal discomfort, and sweating) or improvement in hypersequestration or hemolytic anemia. Reduction in leukocyte count alone was not regarded as response. All responses were partial. The median response duration was 1 year. Subsequently, three patients underwent splenectomy. The median survival from the beginning of spleen irradiation was 2.5 years (range: 1 month-greater than 5 years). Only six patients had minor side effects from the gastrointestinal tract. The hematologic effect was most pronounced on the white blood cell count, but also the platelet count was affected. It is concluded that spleen irradiation is a gentle and effective alternative in CLL patients suffering from splenomegaly (pain and hypersplenism), refractory to chemotherapy and glucocorticosteroids and unfit for splenectomy. Splenic irradiation may also be used with benefit preoperatively before splenectomy in patients with excessive splenomegaly and hypersplenism.
Aabo
K
K
Walbom-Jorgensen
S
S
D000328:Adult; D000368:Aged; D006801:Humans; D007945:Leukemia, Lymphoid / Q000532:radiotherapy* / Q000601:surgery; D008875:Middle Aged; D010166:Palliative Care; D013156:Splenectomy; D013163:Splenomegaly / Q000532:radiotherapy* / Q000601:surgery